Kiran

Bioequivalence Study of Fixed-Dose Combination of Remogliflozin Etabonate 100 mg/Vildagliptin 50 mg with Individual Components in Healthy Indian Male Subjects under Fed Conditions

R. Kodgule, Shashank R Joshi, Jayshree Swain, 2022, Journal of Diabetes and Treatment.

A Randomized, Double-blind, Active-controlled Study of Remogliflozin Etabonate 100 mg plus Teneligliptin 10 mg Twice-daily versus Teneligliptin 20 mg Oncedaily as add-on to Metformin Monotherapy in Indian Diabetic Patients

R. Kodgule, H. Barkate, Sumit, 2022, Journal of Diabetes and Treatment.

Frequency of incidental pathogenic and likely pathogenic germline variants detected via tumor-only mesothelioma genomic profiling

S. Armato, J. Donington, A. Husain, 2022, medRxiv.